Advanced Dose Escalation with East® ESCALATE

East® ESCALATE supports the simulation and analysis of Phase 1 dose escalation trials for determining maximum tolerated dose (MTD), for both single-agent and two-agent designs. ESCALATE provides several modern Bayesian and model-based designs, which are known to outperform traditional 3+3 designs in terms of accuracy and safety.

East ESCALATE Benefits

The addition of the ESCALATE module means East 6 delivers a comprehensive package for all phases of oncology trials.

Statisticians can communicate findings to the clinical team by accessing East’s intuitive graphs and tables.


Single-agent designs:

  • Traditional rule-based algorithms (versions of 3+3)
  • Continual Reassessment Method (CRM; Goodman et al. 1995)
  • Modified Toxicity Probability Model (mTPI; Ji et al. 2010)
  • Bayesian Logistic Regression Model for single agent (BLRM; Neuenschwander et al. 2008)
  • mTPI-2

Two-agent designs

  • Bayesian Logistic Regression Model (combBLRM; Neuenschwander et al. 2015)
  • Product of Independent Beta Probabilities Escalation (PIPE; Mander & Sweeting, 2015)
  • mTPI-2